Exploiting Genetically Modified Dual-Reporter Strains to Monitor Experimental Trypanosoma cruzi Infections and Host-Parasite Interactions
- PMID: 30868525
- DOI: 10.1007/978-1-4939-9148-8_11
Exploiting Genetically Modified Dual-Reporter Strains to Monitor Experimental Trypanosoma cruzi Infections and Host-Parasite Interactions
Abstract
Trypanosoma cruzi is the causative agent of Chagas disease, the most important parasitic infection in Latin America. Despite a global research effort, there have been no significant treatment advances for at least 40 years. Gaps in our knowledge of T. cruzi biology and pathogenesis have been major factors in limiting progress. In addition, the extremely low parasite burden during chronic infections has complicated the monitoring of both disease progression and drug efficacy, even in predictive animal models. To address these problems, we genetically modified T. cruzi to express a red-shifted luciferase. Mice infected with these highly bioluminescent parasites can be monitored by in vivo imaging, with exquisite sensitivity. However, a major drawback of bioluminescence imaging is that it does not allow visualization of host-parasite interactions at a cellular level. To facilitate this, we generated T. cruzi strains that express a chimeric protein that is both bioluminescent and fluorescent. Bioluminescence allows the tissue location of infection foci to be identified, and fluorescence can then be exploited to detect parasites in histological sections derived from excised tissue. In this article, we describe in detail the in vivo imaging and confocal microscopy protocols that we have developed for visualizing T. cruzi parasites expressing these dual-reporter fusion proteins. The approaches make it feasible to locate individual parasites within chronically infected murine tissues, to assess their replicative status, to resolve the nature of host cells, and to characterize their immunological context.
Keywords: Bioluminescence; Chronic Chagas disease; Confocal microscopy; Fluorescence; In vivo imaging; Murine models; Trypanosoma cruzi.
Similar articles
-
Expanding the toolbox for Trypanosoma cruzi: A parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo localisation and phenotyping.PLoS Negl Trop Dis. 2018 Apr 2;12(4):e0006388. doi: 10.1371/journal.pntd.0006388. eCollection 2018 Apr. PLoS Negl Trop Dis. 2018. PMID: 29608569 Free PMC article.
-
In Situ Detection of Dormant Trypanosoma cruzi Amastigotes Using Bioluminescent-Fluorescent Reporters.Methods Mol Biol. 2019;1955:179-186. doi: 10.1007/978-1-4939-9148-8_13. Methods Mol Biol. 2019. PMID: 30868527
-
In Vivo Analysis of Trypanosoma cruzi Persistence Foci at Single-Cell Resolution.mBio. 2020 Aug 4;11(4):e01242-20. doi: 10.1128/mBio.01242-20. mBio. 2020. PMID: 32753495 Free PMC article.
-
A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging.J Biomol Screen. 2015 Jan;20(1):36-43. doi: 10.1177/1087057114552623. Epub 2014 Oct 8. J Biomol Screen. 2015. PMID: 25296657 Free PMC article. Review.
-
Infection by the Sylvio X10/4 clone of Trypanosoma cruzi: relevance of a low-virulence model of Chagas' disease.Microbes Infect. 2009 Nov;11(13):1037-45. doi: 10.1016/j.micinf.2009.07.011. Epub 2009 Aug 4. Microbes Infect. 2009. PMID: 19660570 Review.
Cited by
-
Intracellular DNA replication and differentiation of Trypanosoma cruzi is asynchronous within individual host cells in vivo at all stages of infection.PLoS Negl Trop Dis. 2020 Mar 20;14(3):e0008007. doi: 10.1371/journal.pntd.0008007. eCollection 2020 Mar. PLoS Negl Trop Dis. 2020. PMID: 32196491 Free PMC article.
-
Reporter genes and transgenic Trypanosoma cruzi (Kinetoplastida, Trypanosomatidae): applications for screening new drugs against Chagas disease.Front Med (Lausanne). 2025 May 20;12:1591148. doi: 10.3389/fmed.2025.1591148. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40463976 Free PMC article. Review.
-
A panel of phenotypically and genotypically diverse bioluminescent:fluorescent Trypanosoma cruzi strains as a resource for Chagas disease research.PLoS Negl Trop Dis. 2024 May 31;18(5):e0012106. doi: 10.1371/journal.pntd.0012106. eCollection 2024 May. PLoS Negl Trop Dis. 2024. PMID: 38820564 Free PMC article.
-
Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.JCI Insight. 2021 May 10;6(9):e145523. doi: 10.1172/jci.insight.145523. JCI Insight. 2021. PMID: 33986194 Free PMC article.
-
Trypanosoma cruzi STIB980: A TcI Strain for Drug Discovery and Reverse Genetics.Pathogens. 2023 Oct 4;12(10):1217. doi: 10.3390/pathogens12101217. Pathogens. 2023. PMID: 37887733 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical